中智药业(03737)发布截至2024年12月31日止年度的全年业绩，收益22.15亿元(人民币，下同)，同比增加8.05%;股东应占溢利9521.2万元，同比减少41.51%;每股基本盈利0.11元;拟派发末期股息每股5港仙。

公告称，源自制药的收益增长约14.7%，截至2024年12月31日止年度为16.24亿元(2023年：14.16亿元)，并占年内总收益的73.3%(2023年：69.1%)。收益增加主要由于集团顺应市场变化，集团的销售战略在以破壁饮片、中成药为主的基础上，增加对传统饮片的市场投入。

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.